IDHC — Integrated Diagnostics Holdings Share Price
Last trade - 00:00- $209.28m
- $219.28m
- EGP5.72bn
- 98
- 60
- 46
- 82
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.07 | ||
| PEG Ratio (f) | 0.99 | ||
| EPS Growth (f) | 10.07% | ||
| Dividend Yield (f) | 8.82% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.93 | ||
| Price to Tang. Book | 11.78 | ||
| Price to Free Cashflow | 7.93 | ||
| Price to Sales | 1.86 | ||
| EV to EBITDA | 6.58 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 24.46% | ||
| Return on Equity | 39.99% | ||
| Operating Margin | 21.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | EGPm | 2,656.26 | 5,224.71 | 3,605.05 | 4,122.51 | 5,719.74 | 6,618.59 | 7,341.01 | 20.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +16.26 | +137.81 | -60.72 | -2.53 | +101.37 | +3.53 | +23.63 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Integrated Diagnostics Holdings PLC is a consumer healthcare company. The Company operates in the Middle East and Africa with operations in Egypt, Jordan, Sudan, and Nigeria. The Company is engaged in offering services in immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, histopathology, genetics, radiology, and others. The Company’s brands include Al Borg Scan, Al Mokhtabar, Ultralab, Biolab, Echo-Lab and others. It operates in approximately 601 branches. It offers more than 3,000 diagnostics tests ranging from routine to advanced. Its common tests include those for cholesterol, diabetes, pregnancy, and substance abuse. Through Al Borg Scan, it offers a full range of radiology services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography-computed tomography (PET-CT), electromyography (EMG), electrocardiogram (ECG), electroencephalogram (EEG), ultrasound, x-ray, mammograms and cath lab facilities.
Directors
- Anthony St John NEC (63)
- Hend El Sherbini CEO (52)
- Omar Bedewy CFO
- Richard Phillips NED (56)
- Hussein Choucri NID (70)
- James Nolan NID (61)
- Dan Olsson NID (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 4th, 2014
- Public Since
- May 6th, 2015
- No. of Employees
- 6,692
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 581,326,272
- Address
- 12 Castle Street, SAINT HELIER, JE2 3RT
- Web
- https://www.idhcorp.com/
- Phone
- +44 1534847000
- Contact
- Tarek Yehia
- Auditors
- PricewaterhouseCoopers LLP
Latest News for IDHC
Upcoming Events for IDHC
Integrated Diagnostics Holdings PLC Annual Shareholders Meeting
Integrated Diagnostics Holdings PLC Annual Shareholders Meeting
Similar to IDHC
Chill Brands
London Stock Exchange
CVS
London Stock Exchange
Hellenic Dynamics
London Stock Exchange
IQ-AI
London Stock Exchange
One Health
London Stock Exchange
FAQ
As of Today at 21:20 UTC, shares in Integrated Diagnostics Holdings are trading at $0.36. This share price information is delayed by 15 minutes.
Shares in Integrated Diagnostics Holdings last closed at $0.36 and the price had moved by +4.5% over the past 365 days. In terms of relative price strength the Integrated Diagnostics Holdings share price has outperformed the FTSE All Share Index by +1.63% over the past year.
The overall consensus recommendation for Integrated Diagnostics Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreIntegrated Diagnostics Holdings does not currently pay a dividend.
Integrated Diagnostics Holdings does not currently pay a dividend.
Integrated Diagnostics Holdings does not currently pay a dividend.
To buy shares in Integrated Diagnostics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.36, shares in Integrated Diagnostics Holdings had a market capitalisation of $209.28m.
Here are the trading details for Integrated Diagnostics Holdings:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: IDHC
Based on an overall assessment of its quality, value and momentum Integrated Diagnostics Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Integrated Diagnostics Holdings is $0.58. That is 61.12% above the last closing price of $0.36.
Analysts covering Integrated Diagnostics Holdings currently have a consensus Earnings Per Share (EPS) forecast of EGP1.88 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Integrated Diagnostics Holdings. Over the past six months, its share price has underperformed the FTSE All Share Index by -24.57%.
As of the last closing price of $0.36, shares in Integrated Diagnostics Holdings were trading -6.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Integrated Diagnostics Holdings PE ratio based on its reported earnings over the past 12 months is 9.07. The shares last closed at $0.36.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Integrated Diagnostics Holdings' management team is headed by:
- Anthony St John - NEC
- Hend El Sherbini - CEO
- Omar Bedewy - CFO
- Richard Phillips - NED
- Hussein Choucri - NID
- James Nolan - NID
- Dan Olsson - NID